0000950170-24-028832.txt : 20240308
0000950170-24-028832.hdr.sgml : 20240308
20240308183811
ACCESSION NUMBER: 0000950170-24-028832
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240306
FILED AS OF DATE: 20240308
DATE AS OF CHANGE: 20240308
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kohli Aditya
CENTRAL INDEX KEY: 0001791402
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41365
FILM NUMBER: 24736102
MAIL ADDRESS:
STREET 1: C/O PHATHOM PHARMACEUTICALS, INC.
STREET 2: 2150 E. LAKE COOK ROAD, SUITE 800
CITY: BUFFALO GROVE
STATE: IL
ZIP: 60089
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HilleVax, Inc.
CENTRAL INDEX KEY: 0001888012
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 HARRISON AVE, SUITE 500
CITY: BOSTON
STATE: MA
ZIP: 02118
BUSINESS PHONE: (617) 213-5054
MAIL ADDRESS:
STREET 1: 321 HARRISON AVE, SUITE 500
CITY: BOSTON
STATE: MA
ZIP: 02118
4
1
ownership.xml
4
X0508
4
2024-03-06
0001888012
HilleVax, Inc.
HLVX
0001791402
Kohli Aditya
C/O HILLEVAX, INC.,
321 HARRISON AVE, SUITE 500
BOSTON
MA
02118
true
false
false
false
true
Common Stock
2024-03-06
4
S
false
6000
18.9501
D
837776
D
Common Stock
2024-03-07
4
S
false
6000
18.3688
D
831776
D
Common Stock
2024-03-08
4
S
false
6000
18.6598
D
825776
D
The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person October 12, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices between $18.58 and $19.51. The Reporting Person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices between $17.91 and $18.92. The Reporting Person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices between $18.37 and $18.97. The Reporting Person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Paul Bavier, Attorney-in-Fact for Aditya Kohli
2024-03-08